Emrelis (telisotuzumab vedotin-tllv) Patient Assistance Program
Don’t let the high cost of brand c-Met-directed antibody-drug conjugate disrupt your non-small cell lung cancer treatment. We help eligible patients access Emrelis (telisotuzumab vedotin IV infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Emrelis (telisotuzumab vedotin-tllv) is FDA-approved (accelerated approval, 2025) for previously treated adults with locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression, no EGFR mutations, and prior systemic therapy. First-in-class c-Met-directed antibody-drug conjugate — targets c-Met-overexpressing tumors and delivers an MMAE cytotoxic payload.
- Without assistance, Emrelis costs commonly run approximately $22,000+ per infusion.
- Through AffordMyPrescriptions, qualifying patients can access Emrelis for a flat $69.95 per month.
- Prior NSCLC therapy typically includes platinum chemotherapy (carboplatin/pemetrexed) plus immunotherapy (Keytruda/pembrolizumab) for non-squamous NSCLC without actionable mutations, or targeted therapy for actionable mutations. Emrelis is post-progression therapy for high c-Met-overexpressing NSCLC. Other c-Met-targeted therapies: Tabrecta (capmatinib), Tepmetko (tepotinib) — both for MET exon 14 skipping mutations. Comprehensive molecular testing (NGS) is essential. Oncology specialty required.
What is Emrelis Prescription Assistance Program?
The Emrelis Patient Assistance Program helps eligible patients access Emrelis for c-Met-overexpressing previously treated NSCLC at little or no cost when meeting income, insurance, and clinical criteria. Free to apply but involves detailed applications, oncology coordination, biomarker documentation, and ongoing renewal.
At AffordMyPrescriptions, our Patient Advocates handle the entire Emrelis PAP enrollment for a flat $69.95 per month — so you never face a gap in your Emrelis lung cancer therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Emrelis enrollment — so you never face a gap in your c-Met-overexpressing NSCLC treatment.
Pharmacy Price Comparison
- Without assistance, Emrelis costs tens of thousands per infusion at cancer centers. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Docetaxel (chemo alt) | ~$500/cycle | Generic chemo alt |
| Cancer center pharmacy | ~$23,000/infusion | Save substantially |
| Community oncology | ~$22,000/infusion | Save substantially |
| Hospital outpatient | ~$22,500/infusion | Save substantially |
| 340B-eligible institution | ~$18,000/infusion | Save substantially |
| Tabrecta (MET exon 14 alt) | ~$20,000/mo | For MET exon 14 mut |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Emrelis — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Emrelis Prescription Program?
The Emrelis Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. Biomarker-directed therapy requires validated c-Met testing. Comprehensive NGS molecular testing is critical for NSCLC — many actionable mutations exist. Cancer specialty center consultation is recommended.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Emrelis assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Emrelis is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Emrelis:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $22,000–$23,000/infusion even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Emrelis assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Emrelis Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Emrelis:
Emrelis is the first-in-class c-Met-directed antibody-drug conjugate for c-Met-overexpressing NSCLC — it targets the c-Met surface protein and delivers MMAE (a microtubule inhibitor) cytotoxic payload after cellular internalization. Precision oncology built on a biomarker-defined subpopulation.
How It Works:
Non-small cell lung cancer (NSCLC) is the majority of lung cancers. Molecular profiling identifies actionable driver mutations (EGFR, ALK, ROS1, BRAF, KRAS G12C, HER2, RET, MET exon 14, NTRK) plus biomarkers for immunotherapy selection (PD-L1). c-Met (mesenchymal-epithelial transition factor) is a receptor tyrosine kinase overexpressed in a subset of NSCLC — associated with poor prognosis. Telisotuzumab vedotin is an antibody-drug conjugate: telisotuzumab (anti-c-Met antibody) linked to MMAE (monomethyl auristatin E — a microtubule inhibitor cytotoxin) via a cleavable linker. The antibody binds c-Met on the tumor cell surface, is internalized, the linker is cleaved intracellularly, MMAE is released, and microtubule disruption causes apoptosis — selectively delivering cytotoxin to c-Met-overexpressing tumors. Distinct from c-Met kinase inhibitors (Tabrecta, Tepmetko) which target MET exon 14 skipping mutation tumors.
Form and Use:
Emrelis IV infusion. Weight-based dosing. Every 2 weeks. Given at a cancer center or infusion suite. Requires validated c-Met protein overexpression testing. Continue until disease progression or unacceptable toxicity.
Generic Availability:
No generic Emrelis. Other c-Met-targeted therapies: Tabrecta (capmatinib — small-molecule c-Met inhibitor for MET exon 14 skipping mutations), Tepmetko (tepotinib — similar). Emrelis is for c-Met protein overexpression (not MET exon 14 skipping mutation). Prior NSCLC therapy: platinum chemotherapy + pembrolizumab (Keytruda) for non-squamous without actionable mutations; targeted therapy for actionable mutations (osimertinib for EGFR; various for ALK/ROS1/BRAF/KRAS G12C/HER2/RET/MET exon 14/NTRK). Post-progression options: docetaxel (generic chemo), Cyramza + docetaxel, clinical trials. Comprehensive NGS molecular testing is essential. Lung cancer specialty and NCI-designated cancer centers offer trial access.
Warnings:
Peripheral neuropathy (MMAE payload — common — monitor and hold/reduce for symptoms), interstitial lung disease/pneumonitis (potentially fatal — monitor for respiratory symptoms and imaging), ocular disorders (dry eye, keratitis — ophthalmology monitoring), infusion-related reactions, embryo-fetal toxicity (contraindicated in pregnancy), hepatotoxicity, cytopenias (neutropenia, thrombocytopenia — monitor). Other: nausea, fatigue, decreased appetite, edema, alopecia. Requires validated c-Met overexpression testing. Oncology and ophthalmology follow-up.
FAQ (Frequently Asked Questions)
How much does Emrelis cost without insurance?
$22,000–$23,000 per infusion at cancer centers. With every-2-week dosing, monthly cost is $44,000+. A very expensive novel ADC — Patient Assistance Programs are essential.
What is c-Met overexpression and why does it matter for NSCLC?
c-Met is a cell surface receptor overexpressed in a subset of non-squamous NSCLC, associated with poor prognosis and progression. Emrelis is FDA-approved (accelerated approval) for previously treated NSCLC with high c-Met protein overexpression — a biomarker-defined subpopulation. It requires validated c-Met testing before therapy.
How is Emrelis different from Tabrecta/Tepmetko?
Different mechanisms and biomarkers. Emrelis is an antibody-drug conjugate targeting c-Met protein overexpression — delivering an MMAE cytotoxin. Tabrecta (capmatinib) and Tepmetko (tepotinib) are small-molecule c-Met kinase inhibitors for MET exon 14 skipping mutations — a distinct actionable mutation. Molecular testing determines which applies.
Do I need molecular testing before Emrelis?
Yes — it requires validated c-Met protein overexpression testing (typically IHC). Comprehensive NGS molecular profiling of NSCLC is standard, since many actionable mutations exist. Your oncologist can order testing, which can guide multiple therapy decisions.
What are Emrelis side effects?
Peripheral neuropathy (MMAE payload — very common; monitor and adjust dose), interstitial lung disease/pneumonitis (potentially fatal — monitor imaging and symptoms), ocular disorders (dry eye, keratitis — ophthalmology monitoring), nausea, fatigue, decreased appetite, edema, alopecia, cytopenias, hepatotoxicity, infusion reactions. Oncology and ophthalmology follow-up is essential.
Take Control of Your Medication Costs
Precision therapy for c-Met-overexpressing NSCLC offers new hope for a challenging cancer. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.